| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Yohimbic acid is a weak inhibitor of topoisomerase 1/2 with µM-level activity. It displays vasodilatory effects. As a demethylated analogue of Yohimbine, it may also interact with adrenergic receptors, though further research is needed to identify and characterize its primary molecular targets.
|
|---|---|
| ln Vitro |
Yohimbic acid displays vasodilatory effects. It is a weak inhibitor of topoisomerase 1/2 with µM-level activity. The compound may be utilized in osteoarthritis (OA) research. Further studies are needed to fully characterize its in vitro pharmacological profile and to determine its potency against various targets.
|
| ln Vivo |
Specific in vivo activity data for Yohimbic acid are not extensively reported in the available literature. As a compound with vasodilatory effects, it may exhibit efficacy in preclinical models of cardiovascular disease. It may also be useful in osteoarthritis research. Further research is needed to characterize its pharmacokinetic and pharmacodynamic profiles in animal models.
|
| Enzyme Assay |
The in vitro assay for Yohimbic acid typically involves measuring its effects on enzyme activity or receptor binding using standard biochemical techniques. The compound may be tested for its ability to inhibit topoisomerase 1/2 or to bind to adrenergic receptors. The IC50 value is determined from the dose-response curve.
|
| Cell Assay |
The in vitro cellular assay for Yohimbic acid typically involves culturing relevant cell lines (e.g., vascular smooth muscle cells, cancer cells) in appropriate growth media. Cells are treated with varying concentrations of the compound, and cellular responses such as cell proliferation, vasodilation, or apoptosis are measured using standard assays.
|
| Animal Protocol |
In vivo animal studies for Yohimbic acid would typically involve the use of rodent models of cardiovascular disease or osteoarthritis. Animals would be administered the compound via appropriate routes (e.g., oral gavage or intraperitoneal injection) at various dose levels. Parameters such as blood pressure, vascular function, or joint health would be assessed.
|
| ADME/Pharmacokinetics |
Yohimbic acid has a molecular weight of 340.42 g/mol and a molecular formula of C20H24N2O3. The IUPAC name is (1R,2S,4aR,13bS,14aS)-2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid. The compound has a purity of ≥98%. Further detailed physicochemical properties are available from the manufacturer's data sheets.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Yohimbic acid are not available in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application. Researchers should consult the safety data sheet for detailed handling and disposal information.
|
| References |
|
| Additional Infomation |
Yohimbic acid is a yohimbine alkaloid that functions similarly to 17α-yohimbine.
Yohimbic acid is an amphoteric demethylated analogue of Yohimbine. It is a natural alkaloid found in the bark of the African yohimbe tree (Pausinystalia johimbe). It displays vasodilatory effects and may be utilized in osteoarthritis (OA) research. It has been used in traditional medicine to treat various ailments. The compound is also known by the synonyms NSC-95096 and YOHIMBIC ACID [INN]. It has not yet entered clinical trials and is strictly for preclinical research purposes. |
| Molecular Formula |
C20H24N2O3
|
|---|---|
| Molecular Weight |
340.423
|
| Exact Mass |
340.179
|
| CAS # |
522-87-2
|
| Related CAS # |
Yohimbic acid hydrate;207801-27-2
|
| PubChem CID |
72131
|
| Appearance |
White to off-white solid powder
|
| Density |
1.39g/cm3
|
| Boiling Point |
600ºC at 760mmHg
|
| Melting Point |
267-268ºC (dec.)(lit.)
|
| Flash Point |
316.6ºC
|
| Index of Refraction |
1.702
|
| LogP |
2.496
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
25
|
| Complexity |
541
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1C[C@@H]([C@@H]([C@@H]2[C@@H]1CN3CCC4=C([C@@H]3C2)NC5=CC=CC=C45)C(=O)O)O
|
| InChi Key |
AADVZSXPNRLYLV-GKMXPDSGSA-N
|
| InChi Code |
InChI=1S/C20H24N2O3/c23-17-6-5-11-10-22-8-7-13-12-3-1-2-4-15(12)21-19(13)16(22)9-14(11)18(17)20(24)25/h1-4,11,14,16-18,21,23H,5-10H2,(H,24,25)/t11-,14-,16-,17-,18+/m0/s1
|
| Chemical Name |
(1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid
|
| Synonyms |
NSC 95096; NSC-95096; Yohimbic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~367.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9375 mL | 14.6877 mL | 29.3755 mL | |
| 5 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL | |
| 10 mM | 0.2938 mL | 1.4688 mL | 2.9375 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
